JP6447716B2 - 嚥下障害患者における脳卒中治療用のアミノ酸含有組成物 - Google Patents

嚥下障害患者における脳卒中治療用のアミノ酸含有組成物 Download PDF

Info

Publication number
JP6447716B2
JP6447716B2 JP2017511782A JP2017511782A JP6447716B2 JP 6447716 B2 JP6447716 B2 JP 6447716B2 JP 2017511782 A JP2017511782 A JP 2017511782A JP 2017511782 A JP2017511782 A JP 2017511782A JP 6447716 B2 JP6447716 B2 JP 6447716B2
Authority
JP
Japan
Prior art keywords
composition
patients
stroke
dysphagia
muscle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2017511782A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017530103A (ja
Inventor
ルカ マリア ジオルゲッティ、パオロ
ルカ マリア ジオルゲッティ、パオロ
Original Assignee
プロフェッショナル ダイエテティクス エス．ピー．エー．
プロフェッショナル ダイエテティクス エス．ピー．エー．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by プロフェッショナル ダイエテティクス エス．ピー．エー．, プロフェッショナル ダイエテティクス エス．ピー．エー． filed Critical プロフェッショナル ダイエテティクス エス．ピー．エー．
Publication of JP2017530103A publication Critical patent/JP2017530103A/ja
Application granted granted Critical
Publication of JP6447716B2 publication Critical patent/JP6447716B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A61K31/51—Thiamines, e.g. vitamin B1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2017511782A 2014-10-08 2015-10-07 嚥下障害患者における脳卒中治療用のアミノ酸含有組成物 Expired - Fee Related JP6447716B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ITTO20140806 2014-10-08
ITTO2014A000806 2014-10-08
PCT/IB2015/057662 WO2016055948A1 (en) 2014-10-08 2015-10-07 Compositions comprising amino acids for use in the treatment of stroke in patients with dysphagia

Publications (2)

Publication Number Publication Date
JP2017530103A JP2017530103A (ja) 2017-10-12
JP6447716B2 true JP6447716B2 (ja) 2019-01-09

Family

ID=52101507

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017511782A Expired - Fee Related JP6447716B2 (ja) 2014-10-08 2015-10-07 嚥下障害患者における脳卒中治療用のアミノ酸含有組成物

Country Status (14)

Country Link
US (1) US9707198B2 (enExample)
EP (1) EP3006027B1 (enExample)
JP (1) JP6447716B2 (enExample)
KR (1) KR102077374B1 (enExample)
AU (1) AU2015329581B2 (enExample)
CA (1) CA2958033C (enExample)
DK (1) DK3006027T3 (enExample)
ES (1) ES2651903T3 (enExample)
HU (1) HUE035699T2 (enExample)
NO (1) NO3006027T3 (enExample)
NZ (1) NZ728962A (enExample)
PL (1) PL3006027T3 (enExample)
RU (1) RU2668373C1 (enExample)
WO (1) WO2016055948A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3294279T3 (pl) * 2015-05-14 2020-06-29 Professional Dietetics International S.R.L. Kompozycje zawierające aminokwasy do zastosowania w leczeniu zapalenia błony śluzowej u pacjentów cierpiących na neoplazję poddawanych radioterapii i/lub chemioterapii
IT201700087376A1 (it) * 2017-07-28 2019-01-28 Professional Dietetics Spa Composizioni comprendenti amino acidi per l'uso nel trattamento di malattie associate a disfunzione mitocondriale

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4780475A (en) * 1986-02-03 1988-10-25 Cerra Frank B Preparation for the prevention of catabolism
US5276018A (en) * 1992-07-17 1994-01-04 Brigham And Women's Hospital Composition comprising amino acids and methods for decreasing muscle breakdown
IT1320783B1 (it) * 2000-07-04 2003-12-10 Professional Dietetics Srl Composizioni a base di aminoacidi, atte al miglioramento delleprestazioni muscolari.
US20030060421A1 (en) * 2001-07-19 2003-03-27 Neuron Therapeutics, Inc. Kits and compositions supporting intracranial perfusions
EP2275084A1 (en) * 2009-07-15 2011-01-19 Unilever PLC Oral care composition
RU2012105901A (ru) * 2009-07-20 2013-08-27 Нестек С.А. Способы снижения потери функционального состояния
PH12013501571A1 (en) * 2011-03-01 2013-09-30 Nestec Sa Extensional viscosity to promote safe swallowing of food boluses
WO2012133198A1 (ja) * 2011-03-25 2012-10-04 イーエヌ大塚製薬株式会社 炎症性疾患用栄養組成物
JP2012214451A (ja) * 2011-03-25 2012-11-08 En Otsuka Pharmaceutical Co Ltd 炎症性疾患用アミノ酸組成物
JP5837315B2 (ja) * 2011-03-25 2015-12-24 イーエヌ大塚製薬株式会社 炎症性疾患用栄養組成物
WO2012142678A1 (en) * 2011-04-21 2012-10-26 Fit-Bioceuticals Limited Weight loss composition
RU2526826C2 (ru) * 2012-10-24 2014-08-27 Николай Владимирович Соловьёв Композиция для парентерального введения, способ получения и применение композиции

Also Published As

Publication number Publication date
WO2016055948A1 (en) 2016-04-14
AU2015329581B2 (en) 2019-02-07
AU2015329581A1 (en) 2017-03-02
RU2668373C1 (ru) 2018-09-28
ES2651903T3 (es) 2018-01-30
KR102077374B1 (ko) 2020-02-13
CA2958033A1 (en) 2016-04-14
KR20170057308A (ko) 2017-05-24
NO3006027T3 (enExample) 2018-04-14
JP2017530103A (ja) 2017-10-12
NZ728962A (en) 2019-05-31
CA2958033C (en) 2019-07-16
EP3006027A1 (en) 2016-04-13
US9707198B2 (en) 2017-07-18
US20160101078A1 (en) 2016-04-14
EP3006027B1 (en) 2017-11-15
DK3006027T3 (en) 2017-12-18
PL3006027T3 (pl) 2018-02-28
HUE035699T2 (en) 2018-05-28

Similar Documents

Publication Publication Date Title
Bo et al. A high whey protein, vitamin D and E supplement preserves muscle mass, strength, and quality of life in sarcopenic older adults: A double-blind randomized controlled trial
Rammohan et al. Megestrol acetate in a moderate dose for the treatment of malnutrition-inflammation complex in maintenance dialysis patients
JP5830030B2 (ja) 筋タンパク質合成を刺激するための低カロリー高タンパク質栄養組成物
Dickinson et al. Leucine-enriched amino acid ingestion after resistance exercise prolongs myofibrillar protein synthesis and amino acid transporter expression in older men
de Medeiros Cavalcante et al. Effect of vitamin D3 supplementation and influence of BsmI polymorphism of the VDR gene of the inflammatory profile and oxidative stress in elderly women with vitamin D insufficiency: Vitamin D3 megadose reduces inflammatory markers
JP2014065740A (ja) 高齢者の骨格筋量減少を防止又は改善するためのアミノ酸含有組成物
Aquilani et al. Unaffected arm muscle hypercatabolism in dysphagic subacute stroke patients: the effects of essential amino acid supplementation
Morita et al. Clinical evaluation of changes in biomarkers by oral intake of NMN.
KR102077374B1 (ko) 연하곤란 환자에서 뇌졸중의 치료에서 사용하기 위한 아미노산을 포함하는 조성물
Wicks et al. Sarcopenia, diabetes, and nutritional intervention
CN103082167B (zh) 一种适用于艾滋病患者的复合型肠内营养制剂
US12576068B2 (en) Compositions containing amino acids and methods of using such compositions for treating sarcopenia
US20130267606A1 (en) Use of vitamin k for weight maintenance and weight control
US20150057346A1 (en) Methods of maintaining intramuscular myoglobin levels, maintaining maximal aerobic capacity, and enhancing the oxidative capacity of muscle in a subject
Sen et al. Metformin monotherapy with and without lifestyle changes affects anthropometric parameters, blood pressure, blood glucose, and lipid profile in Indian patients with newly diagnosed type 2 diabetes
Ertuglu et al. Protein–Energy Wasting and Nutritional Interventions in Chronic Kidney Disease
Oyama et al. Jelly-type carbohydrate supplement in healthy subjects suppresses the catabolism of adipose tissue and muscle protein and improves their satisfactions
Deger et al. Nutritional Management of Hemodialysis Patients
CN116600660A (zh) 在未锻炼下改善肌肉量、力量和肌肉功能的β-羟基-β-甲基丁酸(HMB)的组合物和使用方法
EP1964558A1 (en) Pharmaceutical compositions containing intestinal lipase inhibiting substances combined with a chromium dinicotinate o-coordinated complex for use in the treatment and control of obesity and overweight
Kumar Effects of resistance exercise (intensity and volume) with or without leucine enriched protein supplementation on human myofibrillar protein synthesis and cell anabolic signalling
van der Kruka SNACKS: WHAT DOES THE PATIENT WOULD LIKE TO EAT?
Moore et al. MetAP2 Inhibitor Treatment of High-Fat and–Fructose Fed Dogs
Avillion Chapter Disorders of the Endocrine System: Anatomy, Physiology, and Current Treatment Initiatives
CN105998058A (zh) 用于预防和改善胰岛素抵抗的营养组合物及其应用

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20171207

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180829

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180904

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181018

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20181106

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20181119

R150 Certificate of patent or registration of utility model

Ref document number: 6447716

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees